Cargando…

Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design

AIMS: Sleep‐disordered breathing (SDB) is a highly prevalent co‐morbidity in patients with chronic heart failure (CHF) and can play a detrimental role in the pathophysiology course of CHF. However, the best way to manage SDB in CHF remains a matter of debate. Sacubitril–valsartan has been included i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaffuel, Dany, Molinari, Nicolas, Berdague, Philippe, Pathak, Atul, Galinier, Michel, Dupuis, Marion, Ricci, Jean‐Etienne, Mallet, Jean‐Pierre, Bourdin, Arnaud, Roubille, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933955/
https://www.ncbi.nlm.nih.gov/pubmed/29469206
http://dx.doi.org/10.1002/ehf2.12270
_version_ 1783320032939343872
author Jaffuel, Dany
Molinari, Nicolas
Berdague, Philippe
Pathak, Atul
Galinier, Michel
Dupuis, Marion
Ricci, Jean‐Etienne
Mallet, Jean‐Pierre
Bourdin, Arnaud
Roubille, François
author_facet Jaffuel, Dany
Molinari, Nicolas
Berdague, Philippe
Pathak, Atul
Galinier, Michel
Dupuis, Marion
Ricci, Jean‐Etienne
Mallet, Jean‐Pierre
Bourdin, Arnaud
Roubille, François
author_sort Jaffuel, Dany
collection PubMed
description AIMS: Sleep‐disordered breathing (SDB) is a highly prevalent co‐morbidity in patients with chronic heart failure (CHF) and can play a detrimental role in the pathophysiology course of CHF. However, the best way to manage SDB in CHF remains a matter of debate. Sacubitril–valsartan has been included in the 2016 European Society of Cardiology guidelines as an alternative to angiotensin‐converting enzyme inhibitors to further reduce the risk of progression of CHF, CHF hospitalization, and death in ambulatory patients. Sacubitril and valsartan are good candidates for correcting SDB of CHF patients because their known mechanisms of action are likely to counteract the pathophysiology of SDB in CHF. METHODS AND RESULTS: The ENTRESTO‐SAS trial is a 3‐month, multicentric, prospective, open‐label real‐life cohort study. Patients eligible for sacubitril–valsartan treatment (i.e. adults with left ventricular ejection fraction ≤35%, who remain symptomatic despite optimal treatment with an angiotensin‐converting enzyme inhibitor, a beta‐blocker, and a mineralocorticoid receptor antagonist) will be evaluated before and after 3 months of treatment (nocturnal ventilatory polygraphy, echocardiography, laboratory testing, and quality‐of‐life and SDB questionnaires). The primary outcome is the change in the Apnoea–Hypopnoea Index, before and after 3 months of treatment. One hundred twenty patients are required to detect a significant 20% improvement of the Apnoea–Hypopnoea Index with a power of 90% at an alpha risk of 5%. CONCLUSIONS: In the context of the SERVE‐HF study, physicians are waiting for new trials and alternative therapies. We sought to assess in the ENTRESTO‐SAS trial whether sacubitril–valsartan could improve the outcome of SDB in CHF patients.
format Online
Article
Text
id pubmed-5933955
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59339552018-05-10 Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design Jaffuel, Dany Molinari, Nicolas Berdague, Philippe Pathak, Atul Galinier, Michel Dupuis, Marion Ricci, Jean‐Etienne Mallet, Jean‐Pierre Bourdin, Arnaud Roubille, François ESC Heart Fail Study Design AIMS: Sleep‐disordered breathing (SDB) is a highly prevalent co‐morbidity in patients with chronic heart failure (CHF) and can play a detrimental role in the pathophysiology course of CHF. However, the best way to manage SDB in CHF remains a matter of debate. Sacubitril–valsartan has been included in the 2016 European Society of Cardiology guidelines as an alternative to angiotensin‐converting enzyme inhibitors to further reduce the risk of progression of CHF, CHF hospitalization, and death in ambulatory patients. Sacubitril and valsartan are good candidates for correcting SDB of CHF patients because their known mechanisms of action are likely to counteract the pathophysiology of SDB in CHF. METHODS AND RESULTS: The ENTRESTO‐SAS trial is a 3‐month, multicentric, prospective, open‐label real‐life cohort study. Patients eligible for sacubitril–valsartan treatment (i.e. adults with left ventricular ejection fraction ≤35%, who remain symptomatic despite optimal treatment with an angiotensin‐converting enzyme inhibitor, a beta‐blocker, and a mineralocorticoid receptor antagonist) will be evaluated before and after 3 months of treatment (nocturnal ventilatory polygraphy, echocardiography, laboratory testing, and quality‐of‐life and SDB questionnaires). The primary outcome is the change in the Apnoea–Hypopnoea Index, before and after 3 months of treatment. One hundred twenty patients are required to detect a significant 20% improvement of the Apnoea–Hypopnoea Index with a power of 90% at an alpha risk of 5%. CONCLUSIONS: In the context of the SERVE‐HF study, physicians are waiting for new trials and alternative therapies. We sought to assess in the ENTRESTO‐SAS trial whether sacubitril–valsartan could improve the outcome of SDB in CHF patients. John Wiley and Sons Inc. 2018-02-22 /pmc/articles/PMC5933955/ /pubmed/29469206 http://dx.doi.org/10.1002/ehf2.12270 Text en © 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Study Design
Jaffuel, Dany
Molinari, Nicolas
Berdague, Philippe
Pathak, Atul
Galinier, Michel
Dupuis, Marion
Ricci, Jean‐Etienne
Mallet, Jean‐Pierre
Bourdin, Arnaud
Roubille, François
Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
title Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
title_full Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
title_fullStr Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
title_full_unstemmed Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
title_short Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
title_sort impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the entresto‐sas study design
topic Study Design
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933955/
https://www.ncbi.nlm.nih.gov/pubmed/29469206
http://dx.doi.org/10.1002/ehf2.12270
work_keys_str_mv AT jaffueldany impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT molinarinicolas impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT berdaguephilippe impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT pathakatul impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT galiniermichel impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT dupuismarion impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT riccijeanetienne impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT malletjeanpierre impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT bourdinarnaud impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign
AT roubillefrancois impactofsacubitrilvalsartancombinationinpatientswithchronicheartfailureandsleepapnoeasyndrometheentrestosasstudydesign